Insulet Corporation (NASDAQ:PODD) Given Average Rating of “Hold” by Brokerages

Shares of Insulet Corporation (NASDAQ:PODD) have received a consensus recommendation of “Hold” from the twenty-seven ratings firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and fourteen have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $195.40.

A number of brokerages have issued reports on PODD. Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Royal Bank Of Canada dropped their target price on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday. BTIG Research downgraded shares of Insulet from a “buy” rating to a “neutral” rating in a report on Thursday. Bank of America reduced their price target on shares of Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, UBS Group decreased their price objective on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a research note on Thursday, August 6th.

Insulet Trading Up 1.2%

Shares of NASDAQ:PODD opened at $142.85 on Tuesday. The company has a market capitalization of $9.91 billion, a P/E ratio of 26.70, a P/E/G ratio of 1.04 and a beta of 1.10. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The business’s 50 day simple moving average is $155.31 and its 200 day simple moving average is $191.94.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same period in the prior year, the company posted $1.17 EPS. The company’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts anticipate that Insulet will post 6.51 EPS for the current fiscal year.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, supported by strong demand for its Omnipod insulin-delivery system and improved margins. The earnings beat indicates that underlying demand and profitability remain healthy. PODD’s Q2 Earnings Top Estimates, FY’26 Sales View Cut
• Neutral Sentiment: Rosen, Faruqi & Faruqi, the DJS Law Group, Schall Brown & Schwartz, and the Law Offices of Howard G. Smith reminded investors of a pending securities class action and the August 31, 2026, deadline to seek lead-plaintiff status. The announcements largely repeat the same legal information and are not evidence that the claims have been proven. Faruqi & Faruqi Insulet Investor Reminder
• Negative Sentiment: Insulet reduced its fiscal 2026 revenue outlook despite beating quarterly estimates. The lowered sales forecast raises concerns about growth momentum and was identified as the main reason the stock remained under pressure after the earnings release. Insulet Q2 Earnings and Fiscal 2026 Outlook
• Negative Sentiment: Stifel, Benchmark, UBS, and TD Cowen all lowered their price targets to $180, $185, $150, and $144, respectively. JPMorgan reiterated a “Neutral” rating, while Wall Street Zen cut the stock to “Hold,” signaling more cautious expectations for PODD. Analyst Price Target Changes

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Institutional Trading of Insulet

Several large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Insulet during the second quarter worth about $1,018,582,000. Norges Bank acquired a new stake in shares of Insulet in the 4th quarter valued at approximately $300,794,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Insulet during the 2nd quarter valued at approximately $60,615,000. Finally, Deutsche Bank AG bought a new stake in shares of Insulet during the 2nd quarter valued at approximately $51,153,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.